Consequently, targeting TIGIT alongside PD-1 inhibitors may present a novel strategy for addressing ocular tumors and inflammatory disorders, such as uveitis; however, clinical trials are currently in the preliminary stages. Here, PDCD1 is linked to eye neoplasm.